1-(5-氨基戊基)-1H-吡咯-2,5-二酮 2,2,2-三氟乙酸盐 | 222159-87-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(5-氨基戊基)-1H-吡咯-2,5-二酮 2,2,2-三氟乙酸盐
• 中文别名: 1-(5-氨基戊基)-1H-吡咯-2,5-二酮2,2,2-三氟乙酸酯；1-(5-氨基戊基)-1H-吡咯-2,5-二酮2,2,2-三氟乙酸盐
• 英文名称: N-(5-aminopentyl)maleimide trifluoroacetate
• 英文别名: 1-(5-aminopentyl)-1H-pyrrole-2,5-dione 2,2,2-trifluoroacetic acid；1-(5-Aminopentyl)-1H-pyrrole-2,5-dione 2,2,2-Trifluoroacetate；1-(5-aminopentyl)pyrrole-2,5-dione;2,2,2-trifluoroacetic acid
• CAS: 222159-87-7
• 化学式: C₂HF₃O₂*C₉H₁₄N₂O₂
• 分子量: 296.246
• InChiKey: LJWKDXOJBJSKTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.67
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  8

安全信息

• 海关编码：
  2925190090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-(5-氨基戊基)-1H-吡咯-2,5-二酮 2,2,2-三氟乙酸盐 、 6-[2-(叔丁氧羰基)肼基]烟酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以52%的产率得到N-[5-(6'-Boc-hydrazinopyridine-3'-carbonyl)aminopentyl]maleimide
  参考文献：
  名称：

  tech和site的定点定向马来酰亚胺双功能螯合剂的设计和合成。

  摘要：

  一个新的异双功能连接子家族（L1-L9），其末端包含一个三齿供体集合，用于协调{M（CO）（3）}（+）核（M = Tc，Re）和硫醇反应性马来酰亚胺通过将适当的醇衍生物与马来酰亚胺偶联，在Mitsunobu反应条件下方便且高收率地制备了该基团。the配合物[Re（CO）（3）（Lx）] Br（x = 1-9）由配体与（NEt（4））（2）[Re（CO）（ 3）Br（3）]在回流的甲醇中。通过（1）H和（13）C NMR，IR和ESI-MS表征配体及其Re配合物。通过X射线晶体学对配体L4和[Re（CO）（3）（L5）] Br进行了结构表征。配合物[Re（CO）（3）（Lx）] Br（x = 4-6）溶液的光激发引起室温下强烈且长时间的发光（荧光寿命约为16微米）。在室温下，在磷酸盐缓冲液（PBS，pH 7.4）中，配体及其Re配合物在顺丁烯二酰亚胺连接基上与肽和蛋白质的巯基基团平滑反应，

  DOI：

  10.1039/b507096a
• 作为产物：
  描述：

  5-(N-叔丁氧羰基氨基)-1-戊醇 在 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.67h， 生成 1-(5-氨基戊基)-1H-吡咯-2,5-二酮 2,2,2-三氟乙酸盐
  参考文献：
  名称：

  WO2020127602A5

  摘要：

  公开号：

  WO2020127602A5

文献信息

• [EN] ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF<br/>[FR] INDUCTEURS CHIMIQUES DE DÉGRADATION DE BRM CONJUGUÉS À DES ANTICORPS ET MÉTHODES ASSOCIÉES
  申请人：GENENTECH INC

  公开号：WO2022020288A1

  公开（公告）日：2022-01-27

  The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs) that target BRM for degradation, to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where BRM degradation is beneficial.

  本文描述的主题是针对BRM的抗体-CIDE偶联物（Ab-CIDEs），用于降解BRM，以及包含它们的药物组合物，以及它们在治疗BRM降解有益的疾病和症状中的应用。
• Fluorescent compounds
  申请人：Mao Fei

  公开号：US09097667B2

  公开（公告）日：2015-08-04

  The present invention relates to fluorescent dyes. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. In one aspect, the invention provides a compound having a maximal fluorescence excitation wavelength, wherein the compound has a structure of Formula II: F—Y=Ψ  Formula II and wherein Z— is a counterion, Y is a bridge unit permitting electron delocalization between F and Ψ, and F is a moiety having the structure: The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.

  本发明涉及荧光染料。本发明提供了一系列广泛的荧光染料和包含这些染料的试剂盒，适用于标记各种生物分子、细胞和微生物。在一个方面，本发明提供了一种具有最大荧光激发波长的化合物，其中该化合物具有以下结构：F—Y=Ψ，其中Z—是一个反离子，Y是一个桥接单元，允许F和Ψ之间的电子共轭，F是具有以下结构的一个基团：本发明还提供了使用荧光染料进行研究和开发、法医鉴定、环境研究、诊断、预后和/或治疗疾病状况的各种方法。
• Time-lapse monitoring of TLR2 ligand internalization with newly developed fluorescent probes
  作者：Yohei Arai、Kouhei Yokoyama、Yuki Kawahara、Qi Feng、Ippei Ohta、Atsushi Shimoyama、Shinsuke Inuki、Koichi Fukase、Kazuya Kabayama、Yukari Fujimoto

  DOI：10.1039/c7ob03205f

  日期：——

  As a mammalian toll-like receptor family member protein, TLR2 recognizes lipoproteins from bacteria and modulates the immune response by inducing the expression of various cytokines. We have developed fluorescence-labeled TLR2 ligands with either hydrophilic or hydrophobic fluorescence groups. The labeled ligands maintained the inflammatory IL-6 induction activity and enabled us to observe the internalization

  作为哺乳动物的收费样受体家族成员蛋白，TLR2识别细菌中的脂蛋白并通过诱导各种细胞因子的表达来调节免疫应答。我们已经开发了带有亲水或疏水荧光基团的荧光标记的TLR2配体。标记的配体保持了炎性IL-6的诱导活性，使我们能够使用活细胞成像观察TLR2配体的内在化和共定位。荧光标记的TLR2配体在活细胞成像中的延时监控显示，宿主细胞中TLR2 / CD14的表达增强了TLR2配体分子的内在化。
• A Novel Radioiodination Reagent for Protein Radiopharmaceuticals with <scp>l</scp>-Lysine as a Plasma-Stable Metabolizable Linkage To Liberate <i>m</i>-Iodohippuric Acid after Lysosomal Proteolysis
  作者：Kouji Wakisaka、Yasushi Arano、Takashi Uezono、Hiromichi Akizawa、Masahiro Ono、Keiichi Kawai、Yoshiro Ohomomo、Morio Nakayama、Hideo Saji

  DOI：10.1021/jm9606397

  日期：1997.8.1

  Radiochemical design of polypeptides using metabolizable linkages would be attractive to enhance target-selective localization of radioactivity for diagnostic and therapeutic nuclear medicine. However, while use of ester bonds as the linkage allows selective release of the designed radiometabolite from covalently conjugated polypeptides after lysosomal proteolysis in nontarget tissues, low plasma stability of ester bonds causes a decrease in radioactivity levels of the target. In pursuit of new metabolizable linkages that provide stable attachment of radiolabels with polypeptide in plasma while facilitating rapid and selective release of designed radiometabolites of rapid urinary excretion in lysosomes, a new radioiodination reagent with L-lysine as the metabolizable Linkage to liberate m-iodohippuric acid (L-HML) was designed and synthesized. Stabilities of the metabolizable linkage in serum and cleavabilities of the linkage in lysosomal proteolysis in hepatic cells were investigated after conjugation of [I-131]-L-HML with galactosyl-neoglycoalbumin (NGA). For comparison, a radioiodination reagent with an ester bond to release m-iodohippuric acid (MIH) was conjugated with NGA under similar conditions. When incubated in human serum, [I-131]-L-HML-NGA liberated less than 3% of the initial radioactivity after 24 h, whereas [I-125]MIH-NGA released more than 60% of its radioactivity during the same interval. In biodistribution studies, [I-131]-L-HML-NGA demonstrated radioactivity elimination from murine liver at a rate and excretion route similar to [I-125]MIH-NGA. Analyses of murine urine after injection of [I-131]-L-HML-NGA indicated a single radioactivity peak at fractions identical to those of m-iodohippuric acid. Biodistribution studies of radioiodinated NGAs with D-lysine or cadaverine as the linkages demonstrated a delayed elimination rate from murine liver with significantly higher radioactivity being excreted in the feces at 24 h postinjection. Thus, L-HML is the first reagent that allows stable attachment of radiolabel with polypeptide in serum while facilitating selective release of a radiometabolite with rapid urinary excretion from covalently conjugated polypeptides after lysosomal proteolysis at a rate similar to that of ester bonds. Thus, L-HML is potentially useful for the radioiodination of polypeptides for diagnostic and therapeutic purposes.
• SULFONATED XANTHENE DERIVATIVES
  申请人：Molecular Probes Inc.

  公开号：EP0966458B1

  公开（公告）日：2003-08-13